# RadioNano Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/radionano-therapeutics

- Industry: Biotechnology
- Headquarters: Kyoto-shi, Japan
- Website: www.radionano-tx.com
- Total disclosed funding: $1M
- Latest round: Series A (Dec 23, 2024)
- Investors on record: 3

## About

Founded in 2024 and based in Tokyo, Japan, RadioNano Therapeutics Inc. operates as a biologically targeted radiation therapy company. In September 2024, RadioNano Therapeutics Inc. raised JPY 450 million in venture funding from Kyoto University Innovation Capital, Mitsubishi UFJ Capital, DBJ Capital, and Japan Science and Technology Agency. As of 2024, the company is led by its representative and CEO, Masatoshi Chiba.

RadioNano offers a Radio boron neutron capture therapy (BNCT), which is a radiation therapy that selectively targets and destroys cancer cells with minimal damage to healthy tissues. The technology utilizes the nuclear reaction between thermal neutrons and boron to generate alpha particles and lithium nuclei, which kill cancer cells. The firm provides RN-501, a highly hydrophilic boron-containing inorganic nanoparticle designed to kill cancer cells, improving treatment efficacy and reducing side effects.

The company plans to utilize the September 2024 investment raised to accelerate the development of RN-501 for clinical trials and expand the pipeline for cancer treatment.

## Funding rounds

- Series A, Dec 23, 2024, $1M — SMBC Venture Capital, Chushin Venture Capital, Kyoto Capital Partners

## Investors

- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series A
- Chushin Venture Capital (https://capitalatlas.ai/funds/chushin-venture-capital) — Series A
- Kyoto Capital Partners (https://capitalatlas.ai/funds/kyoto-capital-partners) — Series A